Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2024 Financial Results • Third quarter reported revenue of $155 million, an increase of 10% year-over-year • CDMO revenue and orders both up ~20% year-over-year • Overall order intake outpaced sales by 4% • Full year revenue guidance narrowed to range of $630-$639 million WALTHAM, Mass., November 12, 2024 — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on ...

Repligen Corporation (NASDAQ: RGEN ) is a prominent bioprocessing technology company developing equipment for streamlining the production of biological drugs. RGEN concentrates on key areas, such as process intensification, purification and analytics, and fluid management, providing solutions to simplify and enhance the efficiency ofMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree ...

WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at three upcoming investor conferences. The UBS Global Healthcare Conference being held November 11-14 in Rancho Palos Verdes, CA. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on Thursday, November 14, at 10:15 a.m. ET.The Stifel Healthcare Conference being held Novembe ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Repligen (RGEN) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may m ...

Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Peptide Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Peptide Therapeutics was estimated at US$42.1 Billion in 2023 and is projected to reach US$56.2 Billion by 2030, growing at a CAGR of 4.2% from 2023 to 2030. The development of peptide therapeutics has been greatly accelerated by technological advances, enabling the creation of more stable, potent, and targeted therapies. Peptides, ...

WALTHAM, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its Repligen Training & Innovation Center ("RTIC") at its Waltham headquarters. The opening celebration, held on the evening of September 23, attracted a group of over 150 biopharma and CDMO customers. The RTIC buildout, which features product exhibits, purpose-built demonstration areas and technical training space ...

Financial Restatement - The restatement will result in an overstatement of Q1 2023 product revenues by $17.3 million and an understatement of Q4 2023 product revenues by $10.7 million, leading to an aggregate overstatement of $6.6 million for the year ended December 31, 2023[8]. - The anticipated financial impact of the restatement includes an understatement of Q1 2024 product revenues by $1.8 million and Q2 2024 product revenues by $4.8 million[8]. - The company will restate its consolidated financial statements for the year ended December 31, 2023, and for the quarterly periods ended March 31, 2023, June 30, 2023, and September 30, 2023[10]. - The company has not yet finalized the quantification of the income tax expense/benefit impact of the restatement for each respective quarterly or annual period[8]. Revenue Guidance - The company reaffirms its full year 2024 revenue guidance, updating the range to $627 million to $642 million, which includes the previously understated $6.6 million in the first half of 2024[9]. Internal Controls - The company identified a material weakness in internal control over financial reporting related to revenue recognition under ASC 606[11]. - The company is undergoing an internal review to assess the effectiveness of its internal controls and may identify further required changes[11]. Operational Impact - The restatement does not impact the company's overall business operations or previously reported cash and cash equivalent balances[5]. - All open purchase order product units were fully delivered to the customer by June 30, 2024, indicating no anticipated impact of the revenue recognition change beyond this date[7]. One-time Payment - The company received a one-time cash payment of $17.3 million in April 2023 due to the cancellation of two COVID-related non-cancellable product purchase orders[6].

WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the Wells Fargo Healthcare Conference being held September 4-6 in Boston. Olivier Loeillot, President and Chief Executive Officer will participate in an analyst-led discussion on Friday, September 6, at 8:45 a.m. ET. A live webcast of the conference presentation will be accessible through Repligen's Investo ...

The bioprocessing market is preparing for a recovery. The bioprocessing market is about to recover. That's the conclusion from Repligen's (RGEN -1.00%) secondquarter earnings report released earlier in the week and the reason for the stock's 17.7% ascendancy in the week to Friday morning. Repligen and Danaher are seeing budding shoots of recovery A positive view of Repligen's recovery is supported when examining Danaher's recent results, released a week earlier. Danaher is a much larger company selling life ...

Repligen Corporation RGEN reported in-line earnings for its second quarter on Tuesday. The company posted second-quarter sales of $154.1 million, almost in line with the consensus estimate of $154.12 million. The company reported an adjusted EPS of 33 cents, which is in line with the consensus but below $0.53 reported a year ago. Tony J. Hunt, CEO of Repligen, said, "We delivered solid second-quarter revenue of $154 million and first-half revenue of $305 million, achieving our year-to-date sales target. We ...